Wordt geladen...
RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1(185delAG) allele is a common inherited...
Bewaard in:
| Gepubliceerd in: | J Clin Invest |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society for Clinical Investigation
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966309/ https://ncbi.nlm.nih.gov/pubmed/27454289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87033 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|